5-Chloro-N-[6-(1H-imidazol-1-yl)hexyl]-2-thiophene carboxamide | 95059-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Chloro-N-[6-(1H-imidazol-1-yl)hexyl]-2-thiophene carboxamide
• 英文别名: 5-Chloro-thiophene-2-carboxylic acid (6-imidazol-1-yl-hexyl)-amide；5-chloro-N-(6-imidazol-1-ylhexyl)thiophene-2-carboxamide
• CAS: 95059-32-8
• 化学式: C₁₄H₁₈ClN₃OS
• 分子量: 311.835
• InChiKey: VCJHUDQRUNCWKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-氯-2-酰氯噻吩 、 6-(1H-imidazol-1-yl)hexanamine 生成 5-Chloro-N-[6-(1H-imidazol-1-yl)hexyl]-2-thiophene carboxamide
  参考文献：
  名称：

  Substituted N-[.omega.-(1H-imidazol-1-yl)alkyl]-amides

  摘要：

  这份披露描述了一种新颖的N-[.omega.-(1H-咪唑-1-基)烷基]酰胺，具有抑制酶血栓素合成酶的特性。

  公开号：

  US04489089A1

文献信息

• Substituted N-[.omega.-(1H-imidazol-1-yl)alkyl]-amides
  申请人：American Cyanamid Company

  公开号：US04489089A1

  公开（公告）日：1984-12-18

  This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]amides which possess the property of inhibiting the enzyme thromboxane synthetase.

  这份披露描述了一种新颖的N-[.omega.-(1H-咪唑-1-基)烷基]酰胺，具有抑制酶血栓素合成酶的特性。
• Substituted N-(omega-(1H-imidazol-1-yl)alkyl)) amides
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0127727A2

  公开（公告）日：1984-12-12

  This disclosure describes novel N-[ω-(1H- imidazol-I-yl)alkyl]amides which possess the property of inhibiting the enzyme thromboxane synthetase.

  本公开介绍了具有抑制血栓素合成酶特性的新型 N-[ω-(1H-咪唑-I-基)烷基]酰胺。
• US4489089A
  申请人：——

  公开号：US4489089A

  公开（公告）日：1984-12-18
• Thromboxane synthetase inhibitors and antihypertensive agents. 3. N-[(1H-imidazol-1-yl)alkyl]heteroaryl amides as potent enzyme inhibitors
  作者：Jeffery B. Press、William B. Wright、Peter S. Chan、Margie F. Haug、Joseph W. Marsico、Andrew S. Tomcufcik

  DOI：10.1021/jm00389a013

  日期：1987.6

  The title compounds were prepared as the heterocyclic analogues of thromboxane (TX) synthetase inhibitors and antihypertensive agents previously reported from our laboratories. These compounds were at least as active TX synthetase inhibitors as their benzene isosteres with the indole derivatives 50-55 having the most potent enzyme inhibiting activity measured to date in our laboratories. The best compound, 54, is more than 200-fold more potent than the standard, dazoxiben. In contrast, the antihypertensive activity of these series of compounds was no better than their benzene counterparts and is far lower than the isoindoledione derivatives prepared in a related series. The structure-activity relationship results from this study were similar to our previous observations and include the fact that the amide moiety effectively replaces a carboxylic acid for potent TX synthetase inhibition and that a four to six methylene unit separation (approximately 8.5 A) between amide and imidazole moieties achieves maximal activity.